# CARDIFF LEXINGTON CORPORATION (CDIX) · Edgar & Edgarette company card

> Cardiff Lexington (CDIX) grew revenue 39.5% in FY2025 to $12 million, operating margin 9.5% against a 2.0% median for offices & clinics of  doctors of  medicine, equity -8.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 811222 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CDIX) · [JSON](https://www.pops4.com/boards/company/CDIX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $12M |
| Revenue growth, 1 year | 39.5% |
| Revenue growth per year | 4.0% |
| Operating margin | 9.5% (prior year -2.3%) |
| Net margin | -47.7% |
| Operating cash flow | — |
| Capital spending | — |
| Free cash flow | — |
| Cash | $318,535 |
| Long-term debt | $19M |
| Total assets | $29M |
| Total equity | −$2M |
| Equity ÷ assets | -8.5% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -9.49 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Weathered boat · two warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); revenue is hard to predict: its 80% range is ±70%

## Edgarette's reading

Exposure: revenue $11.5M (FY2025), total debt $18.6M. Experience: revenue up 39.5% on the year, up 4.0% a year over 4 years; operating margin 9.5%, up from -2.3%. Soundness: equity -8.5% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $5.8M and $32.6M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $5.2M to $36.9M. A statistical range, not company guidance. Against peers (54 filers, $50M+ revenue, its industry group): operating margin 9.5% against a 2.0% median; growth 39.5% against 13.0%.

Range logged 2026-09-24, receipt 9fe46885141a7d8f, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-01-05 ([filing](https://www.sec.gov/Archives/edgar/data/811222/000168316826000083/0001683168-26-000083-index.htm))

## Recent filings

- 8-K · filed 2026-09-24 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/811222/000168316826007348/0001683168-26-007348-index.htm)
- 8-K · filed 2026-09-04 · 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/811222/000168316826006974/0001683168-26-006974-index.htm)
- 10-Q · filed 2026-08-12 · [filing](https://www.sec.gov/Archives/edgar/data/811222/000168316826006232/0001683168-26-006232-index.htm)
- S-1 · filed 2026-06-11 · [filing](https://www.sec.gov/Archives/edgar/data/811222/000168316826004763/0001683168-26-004763-index.htm)
- 8-K · filed 2026-06-11 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/811222/000168316826004756/0001683168-26-004756-index.htm)
- 10-Q · filed 2026-05-13 · [filing](https://www.sec.gov/Archives/edgar/data/811222/000168316826003791/0001683168-26-003791-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000811222.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=811222

## Cite

POPS4, Edgar & Edgarette: CARDIFF LEXINGTON CORPORATION (CDIX) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/CDIX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.